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Objectives: Transcranial magnetic stimulation (TMS) holds potential promise as a
therapeutic modality for disorders of addiction. Our previous findings indicate that
high-frequency repetitive transcranial magnetic stimulation (rTMS) over the left dorsal–
lateral prefrontal cortex (DLPFC) and low-frequency rTMS over the right DLPFC can
reduce drug craving for methamphetamine. One major issue with rTMS is the duration
of treatment and hence potential dropout rate. Theta burst stimulation (TBS) has
been recently shown to be non-inferior relative to repetitive transcranial magnetic
stimulation for major depression. Here, we aim to compare the clinical efficacy and
tolerability of intermittent and continuous theta burst stimulation protocols targeting
left or right dorsolateral prefrontal cortex on methamphetamine craving in abstinent-
dependent subjects.
Methods: In this randomized single-blind pilot study, 83 abstinent methamphetamine-
dependent subjects from a long-term residential treatment program were randomly
allocated into three groups: intermittent theta burst stimulation (iTBS) over the left
DLPFC (active group), continuous theta burst stimulation (cTBS) over the left DLPFC
(active control group), or cTBS over the right DLPFC (active group) was administered
twice daily over 5 days for a total of 10 sessions. We measured the primary outcome
of cue-induced craving and secondarily sleep quality, depression, anxiety, impulsivity
scores, and adverse effects.
Results: We show a pre- vs. postintervention effect on craving, which, on paired t
tests, showed that the effect was driven by iTBS of the left DLPFC and cTBS of the right
DLPFC, reducing cue-induced craving but not cTBS of the left DLPFC. We did not show
the critical group-by-time interaction. The secondary outcomes of depression, anxiety,
and sleep were unrelated to the improvement in craving in the left iTBS and right cTBS
group. In the first two sessions, self-reported adverse effects were higher with left iTBS
when compared to right cTBS. The distribution of craving change suggested greater
clinical response (50% improvement) with right cTBS and a bimodal pattern of effect
with left iTBS, suggesting high interindividual variable response in the latter.
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Conclusion: Accelerated twice-daily TBS appears feasible and tolerable at modulating
craving and mood changes in abstinent methamphetamine dependence critically while
reducing session length. We emphasize the need for a larger randomized controlled
trial study with a sham control to confirm these findings and longer duration of clinically
relevant follow-up.
Clinical Trial Registration: Chinese Clinical Trial Registry number, 17013610.
Keywords: addiction, transcranial magnetic stimulation, theta burst stimulation, craving, DLPFC (dorsolateral
prefrontal cortex)
INTRODUCTION
Disorders of addiction, or compulsive drug-seeking behaviors
despite adverse negative consequences, are characterized by
abnormal brain network function (Goldstein and Volkow, 2011;
Everitt and Robbins, 2016). Preclinical and translational studies
highlight a prominent role for hypoactivity of the prefrontal
cortex (PFC) with chronic stimulant exposure, leading to
the hypothesis that potentiation of PFC function with brain
stimulation might improve addiction management (Diana et al.,
2017). In the recent decade, non-invasive, repetitive transcranial
magnetic stimulation (rTMS) over the dorsolateral prefrontal
cortex (DLPFC) has been used to treat cue-induced craving or
drug intake across different types of drug dependence, including
methamphetamine, cocaine, and heroin (Shen et al., 2016;
Terraneo et al., 2016; Su et al., 2017). A range of prefrontal neural
regions have been targeted with rTMS including superior frontal
gyrus (Rose et al., 2011) or medial prefrontal cortex (Hanlon et al.,
2017), whereas we focus here on DLPFC targeting. Convergent
evidence has suggested that facilitating the left DLPFC or
inhibiting the right DLPFC may reduce craving and substance
consumption in patients with substance dependence (Zhang
et al., 2019). High-frequency excitatory rTMS of the left DLPFC
has been reported to be effective in cocaine use disorder [e.g.,
15 Hz/8 sessions/100% motor threshold (Terraneo et al., 2016),
15 Hz/10 sessions/100% motor threshold (Politi et al., 2008),
and 10 Hz/single session/90% motor threshold (Camprodon
et al., 2007)] and nicotine use disorder [e.g., high frequency/13
session/120% motor threshold, deep TMS over bilateral lateral
prefrontal and insula (Dinur-Klein et al., 2014), 10 Hz/10
sessions/100% motor threshold, and 20 Hz/8 sessions/110% over
the DLPFC (Amiaz et al., 2009; Sheffer et al., 2018)]. Other
stimulants such as methamphetamine craving similarly decreased
with high-frequency left DLPFC rTMS (10 Hz/5 sessions/80%
motor threshold) (Su et al., 2017), but with enhanced cue craving
observed with low frequency (1 Hz/single session/100% motor
threshold) (Li et al., 2013b). In heroin-dependent subjects, high-
frequency rTMS of the left DLPFC similarly decreased craving
(10 Hz/5 sessions/100% motor threshold) (Shen et al., 2016). In
contrast, alcohol-dependent subjects showed a different response
as a function of laterality with decreased craving with high-
frequency rTMS of the right DLPFC (10 Hz/10 sessions/110%
motor threshold) (Mishra et al., 2010), with no effects on craving
in female alcoholics with high-frequency rTMS of the left DLPFC
(20 Hz/10 sessions/110% motor threshold) (Höppner et al., 2011).
The rTMS protocol is commonly administered for up to 10–
30 min/day with treatment duration lasting between 20 and
30 days. Critically, as treatment compliance is a major issue
in drug addiction, decreasing the duration of treatment might
enhance the likelihood of completed treatment. Here, we focus
on shorter stimulation protocols to reduce session lengths and
visits that might lead to improved accessibility for non-invasive
neuromodulation for addiction management.
Intermittent or continuous theta burst stimulation (iTBS or
cTBS) are TMS protocols that have been shown to, respectively,
enhance or inhibit local brain regional activity with long-lasting
effect (Huang et al., 2005; Suppa et al., 2016). The protocols
involve 600 pulses and requires 3 min for iTBS and 40 s for
cTBS (Huang et al., 2005). Previous studies have demonstrated
that iTBS has shown comparable neurophysiological excitatory
effects to 10 Hz rTMS (Di Lazzaro et al., 2005; Lopez-Alonso
et al., 2014). Continuous TBS for 10 sessions to the medial
prefrontal cortex has shown potential efficacy for cocaine use
disorder (Hanlon et al., 2017). Recently, iTBS was shown in a
randomized trial of major depression to be non-inferior to the
10 Hz rTMS protocol in reducing depressive symptoms with
similar tolerability and safety profiles (Blumberger et al., 2018).
Moreover, iTBS showed similar efficacy to 10 Hz rTMS but,
given its shorter duration, might allow a 10-fold increase in
the number of patients treated in cocaine use disorder (Sanna
et al., 2019). Preliminary studies in major depression have also
reported that twice-daily rTMS appears feasible, tolerable, and
capable of achieving efficacy similar to once-daily rTMS while
reducing treatment course length twofold (McGirr et al., 2015;
Modirrousta et al., 2018; Schulze et al., 2018). A recent study
has also shown accelerated iTBS as a treatment for cocaine
use disorder (Steele et al., 2019). However, no trials have
been published to date that explore the feasibility and clinical
effects achieved with accelerated (twice-daily) TBS approaches in
methamphetamine-dependent patients.
A recent meta-analysis has supported the different left/right
hemispheric roles for craving (e.g., cued craving is associated
with left DLPFC) and impulsivity (e.g., the suppression
of right DLPFC increases the level of impulsive decision
making) (Gordon, 2016). Previous studies have suggested that
potentiation of the left DLPFC and suppression of the right
DLPFC may be effective in reducing cue-induced craving (Li
et al., 2013a; Shen et al., 2016; Terraneo et al., 2016; Yavari
et al., 2016; Diana et al., 2017). Furthermore, iTBS to the left
DLPFC has been shown to produce transsynaptic suppression
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of the right DLPFC (i.e., the dominant hemisphere in right-
handed individuals) via transcallosal connections (George et al.,
1999). In the present study, the rationale for choosing iTBS over
the left DLPFC and cTBS over the right DLPFC is supported
by the above-mentioned studies. We hypothesized that iTBS-
L DLPFC and cTBS-R DLPFC would demonstrate efficacy in
improving craving symptoms and that cTBS-L DLPFC might
act as an active control with an increase in craving symptoms.
We further included other secondary outcome measures to
assess the role of potential confounders given the known effects
of neuromodulation of the DLPFC on mood and impulsivity
measures. Critically, we hypothesized that a twice-daily TBS
would be feasible in methamphetamine use disorder. We
further compared tolerability and self-reported adverse events
across different sessions of treatment and among the three
accelerated TBS protocols.
MATERIALS AND METHODS
Human Subjects
All the participants were right-handed male, 18–60 years old,
and recruited from a long-term residential treatment center.
Inclusion criteria included those whose main diagnosis was
methamphetamine use disorder with a duration of at least
1 year and using more than 0.1 g a day for at least 3 months.
Subjects had a positive urine drug screening test upon admission
to a long-term residential treatment program. Subjects could
use other substances before admission but must have had
only methamphetamine use disorder as their primary addiction
diagnosis (except nicotine use disorder). The diagnosis of
moderate–severe methamphetamine use disorder was confirmed
by a senior psychiatrist [Diagnostic and Statistical Manual of
Mental Disorder, Version V (DSM-V)]. The psychiatrist ruled
out other severe psychiatric disorders including schizophrenia,
bipolar disorder, or severe major depression. Exclusion criteria
included a history of other psychiatric disorders, epilepsy,
cardiovascular complications, and other contraindications to
TMS (e.g., metal implants in the skull). Subject characteristics
and previous methamphetamine use history is reported in
Table 1. In the rehabilitation center, all participants received
standardized rehabilitation including daily physical exercise,
supportive therapy on relapse prevention, but no medications.
As the rehabilitation program is an enforced residential drug
treatment program, participants maintained abstinence in the
study. Ethics approval was granted by the Research Ethics
Boards of Shanghai Mental Health Center, Nanjing Normal
University and the local safety monitoring board (Chinese
Clinical Trial Registry number, 17013610). All participants
provided written informed consent in accordance with the
Declaration of Helsinki.
A total of 83 inpatients were recruited and randomly assigned
(with a computer generated number sequence) into iTBS-L
DLPFC (n = 27), cTBS-L DLPFC (n = 26), and cTBS-R DLPFC
(n = 30) groups. All patients were naive to TMS. Patients
recruited in the study did not participate in other intervention
studies before. All patients received twice-daily TBS over five
consecutive days for a total of 10 sessions. The following were
not included in the data set: six subjects were transferred to
a different rehabilitation center before study onset (one iTBS-
L and five cTBS-L), and three subjects withdrew before study
completion (three cTBS-L). There were no significant differences
in demographic variables (e.g., age, years of drug abuse history,
number of cigarettes smoked per day, monthly dosage, interval
between admission into the rehabilitation center and entry into
the study, baseline craving, sleep quality, depression, anxiety, and
impulsivity) between study completers and non-completers.
DLPFC-TBS Procedures
TBS was applied with a CCY-I TMS instrument (Yiruide Co.,
Wuhan, China), using a figure eight or round-shaped coil for
targeted stimulation over the left or right DLPFC. The TMS
intensity for each individual participant was calculated as 70% of
the resting motor threshold. The motor hand area was localized
by TMS that evoked responses of the contralateral abductor
pollicis brevis (APB) muscle. The resting motor threshold was
determined as the TMS intensity that elicited the APB muscle
responses in 5 out of 10 TMS pulses, which produced five
motor-evoked potentials responses of at least 50 mV in 10 trials
(Kammer et al., 2001) (iTBS-L DLPFC, 28% ± 6%; cTBS-
L DLPFC, 27% ± 6%; cTBS-R DLPFC, 29% ± 7%). The
DLPFC target was located using the Yiruide TMS Location Cap
based on the 10–20 electroencephalography (EEG) system [i.e.,
F3 and F4 localization for the left and right DLPFC, respectively
(Herwig et al., 2003)]. The TMS coil was held above the head
of participants with a customized coil holder, and the handle
of the coil was rotated to a position where the plane of the
coil made an angle of 45◦ relative to the midline, producing a
posterior–anterior current flow within underlying cortical areas.
The procedure used for iTBS is composed of three pulse trains of
50 Hz at 70% resting motor threshold (MT) (based on pilot study
and the tolerance level for most subjects), which was repeated
at 5 Hz (2 s on, 8-s interval) for 3 min (600 pulses in total).
In the case of cTBS, three pulse trains of 50 Hz at 70% resting
MT was repeated at 200 ms for 40 s (600 pulses in total). The
interval of time between the two sessions of treatment delivered
on the same day was ∼4 h. Baseline craving, quality of sleep,
depression, anxiety, and impulsivity were assessed before the first
TBS session (pre-TBS) and, on day 6, the day after the final TBS
session (post-TBS).
Blinding
In this randomized, single-blind study, one experimenter
(who administered the intervention) was not blinded to the
group assignment, while both the participants and another
experimenter (the outcome assessor) were blinded. After all
treatments, we asked them to guess whether they had received
effective or non-effective stimulation and how much they felt
stimulation may have affected them [1 (much worse) to 9 (much
better)] to monitor effectiveness of the blinding.
Measurement
The main outcome measure was the craving score evaluation,
which was performed as previously described (Shen et al., 2016).
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TABLE 1 | Demographic and clinical characteristics of patients.
iTBS-L-D (n = 26) cTBS-L-D (n = 18) cTBS-R-D (n = 30) F P value
Age (years) 31.30 (9.60) 29.50 (5.50) 28.23 (6.24) 1.19 0.31
Education (years) 8.54 (2.45) 9.50 (1.90) 8.18 (1.95) 2.16 0.12
Number of cigarettes smoked/day 8.88 (6.10) 7.33 (2.4) 8.20 (6.08) 0.44 0.65
Duration of meth use (years) 6.50 (3.71) 5.78 (3.39) 6.80 (3.29) 0.49 0.61
Duration of current abstinence (months) 6.80 (5.20) 7.89 (6.70) 5.43 (4.20) 1.29 0.28
Meth use before abstinence (g/month) 18.80 (8.89) 23.88 (7.96) 22.48 (14.03) 1.47 0.24
Interval between admission into the
rehabilitation center and entry into the
study (days)
82.35 (62.99) 101.28 (59.48) 99.37 (71.80) 0.615 0.54
Baseline Craving 65.19 (22.20) 65.83 (22.44) 74.83 (19.14) 1.77 0.18
Baseline PSQI 6.7 (3.1) 7.1 (3.1) 8 (2.7) 1.41 0.25
Baseline BDI 13.6 (7.5) 12.8 (7.2) 17.5 (9.4) 2.405 0.1
Baseline BAI 25 (4.5) 29.1 (9.98) 29.8 (8.83) 2.79 0.07
Baseline BIS-11 80.36 (14.43) 87.22 (14.82) 83.67 (14.07) 1.226 0.30
Data are given as mean (SD). BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory; BIS-11, Barratt Impulsiveness Scale 11.
The patients watched a video showing methamphetamine
intake for 5 min followed by a visual analogue scale (VAS)
to evaluate cue-induced craving scores [range: 0 (no desire
or wanting) to 100 (very high desire or wanting)]. The
same video was used before treatment (pre-TBS) and after
5 days of treatment (post-TBS). Patients were assessed for
cued craving score pre- and posttreatment, which was used
to categorize subjects as responders or non-responders. For
major depression, changes from baseline values were examined
for the 17-item Hamilton Rating Scale in two subject groups
(responders and non-responders) (Bakker et al., 2015). Response
to TMS was defined as 50% symptoms reduction from
pre- to posttreatment (Schulze et al., 2018). Similarly, in
the present study, a TBS responder was defined as having
at least a 50% reduction in cued craving scores post-TBS
compared with baseline.
As the mechanism underlying neuromodulation effects
targeting the DLPFC may be related to effects on other
symptoms, most particularly depression and impulsivity, we
also assessed other secondary outcome measures. The 21-
item Beck Depression Inventory (BDI) and 21-item Beck
Anxiety Inventory (BAI) were used to assess depressive and
anxiety symptoms (Beck et al., 1961; Beck et al., 1988).
The Pittsburgh Sleep Quality Index (PSQI) was used to
assess sleep quality and consists of 19 self-rated items
with 7 components: subjective sleep quality, sleep latency,
sleep duration, sleep efficiency, sleep disturbance, use of
sleep medication, and daytime dysfunction (Buysse et al.,
1989). The 30-item Barratt Impulsiveness Scale-11 (BIS-11)
is a self-report measure of impulsivity that assesses six
different subtypes of impulsivity (attention, motor, self-control,
cognitive complexity, perseverance, and cognitive instability
impulsiveness) (Reise et al., 2013).
Subjects were assessed for nine adverse reactions after
each treatment session including headache, neck pain, scalp
pain, tingling, itching, burning sensations, sleepiness, trouble
concentrating, and acute mood change. Each item was scored on
a scale of 1 (mild)–10 (severe), with the total score recorded as the
sum of all nine items. For tolerability comparisons, each patient’s
mean self-reported total score across all sessions was calculated.
Statistical Analysis
The data were assessed for normality of distribution
(Kolmogorov–Smirnov test) and outliers. For data that were not
normally distributed, non-parametric statistical analyses were
used. There were no outliers. Homogeneity of our intervention
groups for baseline demographic and clinical characteristics
was confirmed. One-way analyses of variance (ANOVAs) or
chi-square test were used to compare group differences for
continuous or dichotomous variable comparisons, respectively.
A two-way repeated measures analysis of variance (RMANOVA)
was used to analyze the effects of TBS on our primary outcome
of cued craving and also our secondary outcomes of sleep
quality, anxiety, depression, and impulsivity between groups,
respectively, with time (pre, post) as a within-subject factor
and group (iTBS-L DLPFC, cTBS-L DLPFC, and cTBS-R
DLPFC) as a between-subjects factor. Two-sided paired t tests
were performed between conditions when a significant main
effect or time × group interaction was observed. Multiple
comparisons were corrected using false discovery rate (FDR)
correction (Benjamini and Yekutieli, 2001). When we observed a
significant TBS effect in craving scores and other clinical indices
(sleep quality, depression, anxiety, and impulsivity), Pearson’s
correlation was conducted in exploratory analyses for each TBS
group separately to test the relationship between the two indices.
Multiple comparisons were corrected for pairwise correlations
using FDR correction.
In a secondary analysis of the cued craving score, the
improvement percentage was calculated as the percentage change
between baseline pre- and post-TBS treatment craving scores.
Kernel density estimate (KDE), a non-parametric method to
estimate the probability density function of a continuous random
variable, was then used to model the distribution of craving
score changes acting as a continuous replacement for the discrete
histogram. The Kolmogorov–Smirnov test showed that the
probability distribution was not normally distributed. We then
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FIGURE 1 | Study flowchart. Eighty-three male methamphetamine-dependent subjects were assigned into three groups for twice-daily theta burst stimulation (TBS)
procedures for continuous 5 days (10 sessions). iTBS, intermittent theta burst stimulation; cTBS, continuous theta burst stimulation.
used the non-parametric Wald–Wolfowitz test to compare the
distributions between groups.
For adverse effects, the total scores for all nine items
(headache, neck pain, scalp pain, tingling, itching, burning
sensations, sleepiness, trouble concentrating, and acute mood
change) after each treatment were calculated and compared
using a two-way RMANOVA with treatment sessions (1–
10) as a within-subject factor and group as a between-
subjects factor. The total scores for each adverse event were
analyzed using one-way ANOVA. Further paired t tests were
all FDR corrected.
For blinding effectiveness, the self-report ratings after all
treatments were compared using the Kruskal–Wallis Test with
group as a factor.
All data were analyzed by IBM SPSS Statistics version 20.1
(IBM Inc., New York, NY, United States) and Matlab R2014b
(MathWorks, MA, United States) environments. The statistical
significance threshold was set at P < 0.05 (two-tailed).
RESULTS
Seventy-four subjects completed 5 days of treatment (iTBS-
L DLPFC, N = 26; cTBS-L DLPFC, N = 18 and cTBS-R
DLPFC, N = 30) (Figure 1). There were no group differences
at baseline in age, years of drug abuse history, number of
cigarettes smoked per day, monthly dosage, interval between
admission into the rehabilitation center and entry into the
study, baseline craving, sleep quality, depression, anxiety, and
impulsivity (Table 1).
Effects of TBS on Craving, Sleep Quality,
Mood, and Impulsivity
Table 2 shows the results of ANOVAs conducted for cue-
induced craving, sleep quality, mood, anxiety, and impulsivity.
The craving score showed a significant main effect of time
(F1,73 = 21.01, P < 0.001, η2 = 0.23), suggesting that craving
TABLE 2 | Results of the ANOVAs conducted for craving, PSQI, BDI, BAI, and
BIS.
Measure Source df F Sig. η2
Cued-Craving Time 1 21.01 <0.001 0.23
Group 2 0.47 0.63 0.01
Time × group 2 2.00 0.14 0.05
PSQI Time 1 38.35 <0.001 0.35
Group 2 3.68 0.03 0.09
Time × group 2 3.38 0.04 0.09
BDI Time 1 49.64 <0.001 0.41
Group 2 0.17 0.84 0.005
Time × group 2 3.05 0.05 0.08
BAI Time 1 9.06 0.004 0.11
Group 2 4.05 0.02 0.10
Time × group 2 0.27 0.76 0.008
BIS Time 1 0.18 0.68 0.002
Group 2 0.75 0.48 0.02
Time × group 2 0.74 0.48 0.02
Pittsburgh Sleep Quality Index (PSQI); BDI, Beck Depression Inventory; BAI, Beck
Anxiety Inventory; BIS, Barratt Impulsiveness Scale.
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improved pre- vs. post-intervention. To assess the role of
specific conditions, two-sided paired t tests (FDR corrected)
were used to compare craving scores before and after treatment.
As shown in Figure 2A, iTBS-L DLPFC (P = 0.01) and cTBS-
R DLPFC (P = 0.001) significantly reduced craving scores but
not cTBS-L DLPFC (P = 0.52) (Figure 2A). There were no
significant main effects of group (F2,146 = 0.47, P = 0.63,
η2 = 0.01) nor time × group interaction (F2,146 = 2, P = 0.14,
η2 = 0.05).
KDE of the distribution functions for percentage
improvement (cue-induced craving) from pretreatment for
each group is shown in Figure 3. The Kolmogorov–Smirnov
test indicated that the distribution of percent change in craving
was not normal for iTBS-L DLPFC (D = 0.32, P = 0.006),
cTBS-L DLPFC (D = 0.37, P = 0.02), and cTBS-R DLPFC
(D = 0.33, P = 0.003). We showed a significant difference in the
probability distribution between iTBS-L DLPFC and cTBS-L
DLPFC (Wald–Wolfowitz test, P = 0.03) with a marginally
significant difference between cTBS-L DLPFC and cTBS-R
DLPFC (P = 0.06). In the cTBS L-DLPFC group, patients’
craving symptoms in three responders (16.67%) improved on
average by 45 points (from 65 to 20; 95% CI, −9.1 to 99.1).
In contrast, craving scores in 11 responders (36.67%) in the
cTBS R-DLPFC group and 6 responders (23.08%) in the iTBS
L-DLPFC group demonstrated improvements of 57.3 (from 72.7
to 15.4; 95% CI, 41.9–72.6) and 55 (from 66.7 to 11.7; 95% CI,
40.5–69.5), respectively.
The sleep quality score demonstrated a main effect of time
(F1,73 = 38.35, P < 0.001, η2 = 0.35) and group (F2,146 = 3.68,
P = 0.03, η2 = 0.09) and a time× group interaction (F2,146 = 3.38,
P = 0.04, η2 = 0.09). In the cTBS-L DLPFC (P = 0.009, FDR
corrected) and iTBS-L DLPFC (P = 0.0002, FDR corrected)
groups, sleep quality scores showed a significant reduction or
improvement with no differences shown with cTBS-R DLPFC
(P = 0.08, FDR corrected) (Figure 2B). Thus, although sleep
quality improved pre- vs. posttreatment, this was driven by the
cTBS-L and iTBS-L relative to cTBS-R DLPFC groups.
Repeated measures analysis of variance for depressive
symptom scores indicated a main effect of time (F1,73 = 49.64,
P< 0.001, η2 = 0.41), suggesting an overall pre- vs. posttreatment
improvement. As shown in Figure 2C, compared to baseline,
there was a significant decrease in all posttreatment depression
scores (iTBS-L DLPFC, P = 0.0009; cTBS-L DLPFC, P = 0.001;
cTBS-R DLPFC, P = 0.0005; FDR corrected). Neither a significant
main effect of group (F1,73 = 0.17, P = 0.84, η2 = 0.005)
nor time × group interaction (F2,146 = 3.05, P = 0.05,
η2 = 0.08) was found.
Repeated measures analysis of variance for anxiety scores
suggested a main effect of time (F1,73 = 9.06, P = 0.004, η2 = 0.11)
and group (F2,146 = 4.05, P = 0.02, η2 = 0.1). In the post hoc
analysis, only iTBS-L DLPFC showed a decrease in anxiety
scores (P = 0.001, FDR corrected) (Figure 2D). The interaction
of time × group (F2,146 = 0.27, P = 0.76, η2 = 0.008) was
not significant.
Repeated measures analysis of variance for impulsivity
revealed neither a main effect nor interaction (Table 2 and
Figure 2E).
Correlation Analyses Between Changes
Across Different Clinical Indexes
We conducted exploratory analyses on the primary outcome
measure of craving and secondary outcome measures to assess
potential relationships to other clinical outcomes. A positive
correlation of changes between craving and sleep quality (r = 0.56,
P = 0.045, FDR corrected) and craving and depression (r = 0.495,
P = 0.037, FDR corrected) was observed in the cTBS-L DLPFC
group but critically not in the iTBS-L DLPFC and cTBS-R DLPFC
groups, both of which demonstrated significant improvement in
craving with intervention. Changes between sleep quality and
anxiety in cTBS-L DLPFC was significantly correlated (r = 0.519,
P = 0.003, FDR corrected). In the cTBS-R DLPFC group, changes
between depression and anxiety were also significantly correlated
(r = 0.707, P = 0.001, FDR corrected) (Figure 4).
Adverse Reactions
All treatments were safe, and no seizures were reported. For
the mean self-reported adverse reactions total score after each
treatment, RMANOVA showed a main effect of treatment
sessions (F9,657 = 13.37, P < 0.001, η2 = 0.47) and treatment
sessions × group interaction (F18,1,314 = 3.89, P = 0.001,
η2 = 0.27). Further analysis suggested that total score of adverse
reactions in cTBS-R DLPFC was significantly lower than in
iTBS-L DLPFC after the first treatment session (P = 0.01,
FDR corrected) and second treatment session (P = 0.04, FDR
corrected) (Figure 5A). As shown in Figure 5B and Table 3,
the cTBS-L DLPFC group exhibited the lowest percentage
(5.5%, 17 out of 18) of adverse effects after the last treatment,
and the cTBS-R DLPFC and iTBS-L group demonstrated mild
adverse reactions.
Blinding Effectiveness
For the self-report ratings after all treatments, Kruskal–Wallis test
displayed no significant main effect of group (P = 0.906).
DISCUSSION
Adherence to treatment is a major issue in disorders of addiction.
Our findings indicate the possible efficacy and tolerability of
accelerated twice-daily iTBS-left or cTBS-right DLPFC treatment
over 5 days in reducing craving for methamphetamine but not
cTBS-left DLPFC. To our knowledge, this is the first single-
blind randomized trial to systematically compare the effects
of accelerated TBS procedures for methamphetamine craving
targeting the DLPFC. All three interventions similarly improved
mood scores, and iTBS-left TBS also improved sleep and anxiety
scores, as there was no relationship with craving improvements,
our craving findings may be a primary effect. Our findings
converge with previous observations of efficacy of high-frequency
rTMS of the left DLPFC and low-frequency rTMS of the right
DLPFC to modulate craving in disorders of addictions (Li et al.,
2013a; Shen et al., 2016; Terraneo et al., 2016; Yavari et al., 2016;
Diana et al., 2017). Studies reporting alternate outcomes may be
related to difference in TMS protocols or in efficacy as a function
of the substance (Mishra et al., 2010; Höppner et al., 2011). These
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FIGURE 2 | Theta burst stimulation (TBS) intervention on cue-induced craving, quality of sleep, depression, anxiety, and impulsivity scores. The y-axis shows mean
scores before and after treatment sessions on (A) cue-induced craving, (B) sleep quality, (C) depressive symptoms, (D) anxiety symptoms, and (E) impulsivity (red,
intermittent theta burst stimulation of the left dorsolateral prefrontal cortex (iTBS-L DLPFC); green, continuous TBS of the left DLPFC (cTBS-L DLPFC); blue,
continuous TBS of the right DLPFC (cTBS-R DLPFC). Multiple comparisons were corrected using false discovery rate (FDR) correction, *P < 0.05, **P < 0.01,
***P < 0.001; error bars denote SEM).
FIGURE 3 | The response distribution curve. Kernel density estimates of cued-craving distributions (shown as percentage improvement from pre- to posttreatment)
in methamphetamine-dependent patients (N = 74) who were receiving either intermittent TBS of the left dorsolateral prefrontal cortex (iTBS-L DLPFC) (red), or
continuous TBS of the left DLPFC (cTBS-L DLPFC) (green) or continuous TBS of the right DLPFC (cTBS-R DLPFC) (blue). A TBS responder was defined as having at
least a 50% reduction in cued craving scores post-TBS compared with baseline.
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FIGURE 4 | Correlations between changes between clinical outcomes in three groups. The Pearson correlation between changes in (A) cue-induced craving and
sleep quality, (B) cue-induced craving and anxiety level, and (C) cue-induced craving and depression level. (D) Sleep quality and anxiety level and (E) sleep quality
and depression level. (F) Anxiety level and depression level. The three treatment groups were assessed separately showing the effects of theta burst stimulation
(TBS) between clinical symptoms: intermittent TBS of the left dorsolateral prefrontal cortex (iTBS-L DLPFC) (red), continuous TBS of the left DLPFC (cTBS-L DLPFC)
(green), or continuous TBS of the right DLPFC (cTBS-R DLPFC) (blue).
findings suggest that the shorter TBS procedure might serve
comparably to other standard rTMS procedures in substance
use disorder patients and possibly be relevant dimensionally
across a range of clinical symptoms. We emphasize the need
for a randomized controlled trial study with a sham control to
confirm these findings.
The distribution of the percent change in the primary outcome
of cue-elicited craving offered a more fine-grained comparison.
We observed the highest percentage of responding, defined
as a clinically relevant 50% change in craving, in the cTBS-
right DLPFC group. The distributions of all three interventions
were not normal, suggesting high interindividual variability to
differing TBS protocols. For instance, iTBS-left DLPFC treatment
may have two subgroups, with one markedly improving and
a second with limited change. As this is a small sample size,
further larger studies are required to address these interindividual
differences in responses to neuromodulation (Li et al., 2015;
Suppa et al., 2016).
TBS of the prefrontal cortex might act by enhancing aberrant
prefrontal and downstream network function, decreasing
aberrant excitability or plasticity or influencing downstream
dopaminergic function. Methamphetamine increases synaptic
dopamine levels by blocking dopamine reuptake and increasing
reverse transport via the dopamine transporter. The chronic
use of methamphetamine is associated with impairments in
cognition, mood, and sleep (Cruickshank and Dyer, 2009);
thus, normalizing mood and sleep symptoms may secondarily
improve the secondary consequences of long-term amphetamine
use. Chronic psychostimulants are associated with prefrontal
hypofunction with impairments related to DLPFC function,
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FIGURE 5 | Self-reported adverse effects of twice-daily theta burst stimulation over 10 sessions. (A) Mean total scores of adverse effects (headache, neck pain,
scalp pain, tingling, itching, burning sensations, sleepiness, trouble concentrating, and acute mood change) after each theta burst stimulation (TBS) treatment
session (intermittent TBS of the left dorsolateral prefrontal cortex (iTBS-L DLPFC) (red), continuous TBS of the left DLPFC (cTBS-L DLPFC) (green), or continuous
TBS of the right DLPFC (cTBS-R DLPFC) (blue). Multiple comparisons were corrected false discovery rate (FDR) correction (*P < 0.05; error bars denote SEM).
(B) Percentage with adverse effects across all participants after each treatment session (red, iTBS-L DLPFC; green, cTBS-L DLPFC; blue, cTBS-R DLPFC).
TABLE 3 | Scores of adverse reactions.
iTBS-L-D (n = 26) cTBS-L-D (n = 18) cTBS-R-D (n = 30) ANOVA P value Post hoc (FDR correcteda)
Headache 1.88 (3.49) 3.67 (5.35) 0.57 (2.0) F = 4.23 0.02 cTBS-L > iTBS-L
cTBS-L > cTBS-R
Neck pain 0 (0) 0.11 (0.47) 0 (0) F = 1.58 0.21 NA
Scalp pain 0.92 (3.30) 2.38 (4.50) 0.17 (0.53) F = 3.16 0.05 cTBS-L > iTBS-L
cTBS-L > cTBS-R
Tingling 5.35 (7.10) 5.06 (5.98) 3.90 (7.32) F = 0.34 0.72 NA
Itching 0 (0) 0.11 (0.47) 0 (0) F = 1.59 0.21 NA
Burning Sensation 0 (0) 0.27 (0.83) 0 (0) F = 3.21 0.05 NA
Sleepiness 11.61 (18.23) 1.28 (2.49) 6.80 (15.14) F = 2.69 0.08 NA
Trouble 0 (0) 1.44 (2.15) 0.233 (1.28) F = 6.91 0.002
Concentrating cTBS-L > iTBS-L
cTBS-L > cTBS-R
Mood Change 0.31 (1.57) 2.44 (4.68) 0.17 (0.91) F = 5.19 0.008 cTBS-L > iTBS-L
cTBS-L > cTBS-R
Data are presented as mean (SD). aMultiple comparisons were corrected by the false discovery rate (FDR) correction.
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including executive deficits such as working memory, planning,
and goal-directed control (Goldstein and Volkow, 2011; Voon
et al., 2015). TBS might thus improve DLPFC function and its
associated fronto-striatal network. TMS of the DLPFC paired
with functional imaging has shown a decrease in orbitofrontal
activity associated nicotine cue-induced craving, particularly
when the cue was immediately available, thus implicating
a role in intertemporal discounting (Hayashi et al., 2013).
Psychostimulants are linked to long-term downregulation of
dopaminergic neurotransmission with lower D2/3 receptor levels
and blunted dopamine release to psychostimulants (Volkow
et al., 2004; Koob and Volkow, 2010). Methamphetamine,
in particular, is associated with lower dopamine transporter
levels, which can improve with abstinence (Volkow et al.,
2001). The downstream influence of TMS to the DLPFC
affects caudate synaptic dopamine release in healthy controls
(Strafella et al., 2001) and thus may play a role in normalizing
methamphetamine-related aberrant dopaminergic function.
Further studies are required to assess the underlying mechanisms.
The original TBS neurophysiological study employed 80%
active MT targeting the primary motor cortex (Huang et al.,
2005), while other clinical trials have also tried 120% resting
MT of the DLPFC demonstrating both safety and tolerability
(Blumberger et al., 2018). Our previous study has shown that
TBS (single session/80% motor threshold) over the motor
cortex cannot induce cerebral plasticity, which indicates that
neuroplasticity is supposed to be altered in methamphetamine
users (Huang et al., 2017). The TBS-related plasticity and
behavioral change might highly depend on the intensity, the total
number of pulses, the number of sessions, and the stimulating
site. In the present study, we adopted 70% resting MT intensity
at DLPFC and show in this pilot study that this threshold is both
effective and tolerable for most subjects. The percentage of self-
reported adverse events across the sessions reduced from >50 to
∼20% within the different groups, suggesting enhanced tolerance
and adaptation with repeated TBS. We show that a lower intensity
(70% resting MT) for TBS might still be effective and perhaps
enhance tolerability.
Treatment outcomes appeared to be differentially modulated
among the three groups. Notably, the decreases in depression
score were moderate (40–50%) across all protocols, suggesting
a potential clinically significant response. We did not observe
changes in impulsivity as measured using questionnaires.
Previous studies have reported that cTBS but not iTBS of the right
DLPFC reduced impulsive choice as measured using the delay-
discounting task in healthy subjects and pathological gambling
subjects (Cho et al., 2010; Zack et al., 2016).
Several limitations should be considered. This study focused
on the effects of craving to drug cues without long-term
follow-up to assess the duration of effect and impact on
clinically valid outcomes such as relapse rate or the relationship
to natural rewards. Whether fewer or more sessions (e.g.,
8 sessions over 4 days or 20 sessions as compared to 10
sessions), a shorter interval between sessions, or a greater
number of sessions per day may have a different effect
remains to be investigated. The use of placebo or sham TMS
in larger sample sizes would be of utility for comparison
purposes, although issues have also been highlighted with
the use of other forms of control groups (Davis et al.,
2013). We note the larger number of dropouts in the cTBS-
L DLPFC condition, thus limiting its utility as an active
control; indeed, if fewer subjects had dropped out, we
may have demonstrated the critical group main effect and
interaction effect. Moreover, the use of neurophysiological
or neuroimaging modalities would also be indicated to
explore underlying mechanisms and differences underlying
interindividual differences or for outcome prediction (Hawco
et al., 2018). We applied iTBS over the left DLPFC but
neither the right DLPFC nor a wait-list group due to technical
reasons, including the limited number of methamphetamine-
dependent subjects who could be recruited and the length of
the experiment. The clinical effects of iTBS over the right
DLPFC and a wait-list group in methamphetamine-dependent
subjects should be further investigated. Finally, given that
patients were recruited from an ongoing rehabilitation center
training program, the findings should be interpreted with
caution since daily physical exercise and supportive therapy or
individual psychological therapy might alter sleep or mood status.
However, crucially, subjects across all groups experienced the
same non-TBS-related interventions, and we further show that
the improvements in mood and sleep were unrelated to the
improvement in craving.
CONCLUSION
Our findings add to the growing evidence that accelerated
TBS might be an efficacious method for craving, mood,
sleep, and anxiety symptoms and tolerability in abstinent
methamphetamine-dependent subjects. Further larger
randomized studies with placebo control and comparisons
with standard TBS or standard rTMS protocols are indicated.
Critically, our results suggest that the use of both TBS
and an accelerated design might show efficacy in targeting
methamphetamine craving and emphasize efficiency, potentially
facilitating the number of patients that can be treated with each
TMS machine and shortening the duration of treatment from
several weeks to 1 week.
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